StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for SLN yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $7.09 | $6.10 | -13.96% | 0.2M |
| 05-18 | $6.11 | $6.23 | +1.96% | 0.4M |
| 05-19 | $6.04 | $5.77 | -4.47% | 0.3M |
| 05-20 | $5.82 | $6.24 | +7.22% | 0.2M |
| 05-21 | $6.12 | $6.49 | +6.05% | 0.1M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $422.00K | $559.00K | $525.00K | $366.00K |
Operating Income | $-15.74M | $-91.08M | $-78.62M | $-52.37M |
Net Income | $-14.96M | $-88.61M | $-76.84M | $-27.35M |
EPS (Diluted) | $-0.11 | $-0.63 | $-0.54 | $-0.39 |
Total Assets | $115.12M | $131.44M | $146.79M | $165.23M |
Total Liabilities | $65.72M | $69.14M | $72.73M | $71.08M |
Cash & Equivalents | $5.66M | $11.28M | $82.03M | $41.74M |
Free Cash Flow OCF − CapEx | $-15.60M | $-62.33M | $-45.04M | $-34.15M |
Shares Outstanding | 141.70M | 141.70M | 141.70M | 141.70M |
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.